Vanhoecke B, De Ryck T, Stringer A, Van de Wiele T, Keefe D
Faculty of Bioscience Engineering, Laboratory of Microbial Ecology and Technology, Ghent University, Ghent, Belgium; Department of Medicine, Mucositis Research Group, The University of Adelaide, Adelaide, SA, Australia.
Oral Dis. 2015 Jan;21(1):17-30. doi: 10.1111/odi.12224. Epub 2014 Feb 25.
Oral mucositis in patients undergoing cancer therapy is a significant problem. Its prevalence ranges between 20 and 100%, depending on treatment type and protocols and patient-based variables. Mucositis is self-limiting when uncomplicated by infection. Unfortunately, the incidence of developing a local or systemic infection during the course of the treatment is very high. At this stage, it is unclear which role oral microbiota play in the onset, duration, and severity of oral mucositis. Nevertheless, there is growing interest in this underexplored topic, and new studies are being undertaken to unravel their impact on the pathogenesis of mucositis.
接受癌症治疗的患者发生口腔黏膜炎是一个重大问题。其发生率在20%至100%之间,具体取决于治疗类型、方案以及基于患者的变量。若不伴有感染,黏膜炎具有自限性。不幸的是,在治疗过程中发生局部或全身感染的发生率非常高。目前尚不清楚口腔微生物群在口腔黏膜炎的发生、持续时间和严重程度中发挥何种作用。然而,人们对这个研究不足的主题越来越感兴趣,并且正在开展新的研究以阐明它们对黏膜炎发病机制的影响。